WHIPPANY, N.J., Feb. 15, 2017 /PRNewswire/ -- Bayer announced today that its latest research findings on Xofigo® (radium Ra 223 dichloride) injection will be presented at the 2017 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU) taking place February 16 – 18 in Orlando. Among the data being presented are findings from an international early access program (iEAP) study of radium-223.

"Our research efforts are focused on finding treatment options to help patients across disease states," said Dario Mirski, M.D., Bayer's senior vice president and head of U.S. Medical Affairs. "These data being presented at ASCO GU reflect Bayer's commitment to exploring the full clinical utility of radium-223."

Bayer's radium-223 data at ASCO GU 2017 includes:
Radium Ra 223 Dichloride (radium-223)

Relationship Between Quality of Life and Overall Survival in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients in ALSYMPCA
Board G6, Abstract 177, Poster Session A: Prostate Cancer
Thursday, February 16: 11:30 AM-1:00 PM and 5:15 PM-6:15 PM

Effects of Radium-223 (Ra-223) With Docetaxel Versus Docetaxel Alone on Bone Biomarkers in Patients With Bone-Metastatic Castration-Resistant Prostate Cancer (CRPC): A Phase 1/2a Clinical Trial
Board F8, Abstract 154, Poster Session A: Prostate Cancer
Thursday, February 16: 11:30 AM-1:00 PM and 5:15 PM-6:15 PM

Radium-223 (Ra-223) in asymptomatic metastatic castration resistant prostate cancer (mCRPC) patients treated in an international early access program (iEAP)
Board F12, Abstract 158, Poster Session A: Prostate Cancer
Thursday, February 16: 11:30 AM-1:00 PM and 5:15 PM-6:15 PM

Evaluation of Treatment Patterns and Cost for Patients with Prostate Cancer and Bone Metastases
Board H17, Abstract 217, Poster Session A: Prostate Cancer
Thursday, February 16: 11:30 AM-1:00 PM and 5:15 PM-6:15 PM


About Xofigo® (radium Ra 223 dichloride) Injection
Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.1

Important Safety Information for Xofigo® (radium Ra 223 dichloride) Injection

Contraindications: Xofigo is contraindicated in women who are or may become pregnant. Xofigo can cause fetal harm when administered to a pregnant woman.

Bone Marrow Suppression: In the randomized trial, 2% of patients in the Xofigo arm experienced bone marrow failure or ongoing pancytopenia, compared to no patients treated with placebo. There were two deaths due to bone marrow failure. For 7 of 13 patients treated with Xofigo bone marrow failure was ongoing at the time of death. Among the 13 patients who experienced bone marrow failure, 54% required blood transfusions. Four percent (4%) of patients in the Xofigo arm and 2% in the placebo arm permanently discontinued therapy due to bone marrow suppression. In the randomized trial, deaths related to vascular hemorrhage in association with myelosuppression were observed in 1% of Xofigo-treated patients compared to 0.3% of patients treated with placebo. The incidence of infection-related deaths (2%), serious infections (10%), and febrile neutropenia (<1%) was similar for patients treated with Xofigo and placebo. Myelosuppression – notably thrombocytopenia, neutropenia, pancytopenia, and leucopenia – has been reported in patients treated with Xofigo.Monitor patients with evidence of compromised bone marrow reserve closely and provide supportive care measures when clinically indicated. Discontinue Xofigo in patients who experience life-threatening complications despite supportive care for bone marrow failure.

Rad Oncology Homepage